Drug intelligence / Profile preview

BPX-02

Development stage: Preclinical
Lead developer: LEO Pharma
Administration: Topical

Overview

**BPX-02** is a topical biologic drug formulation developed by BioPharmX using proprietary HyantX™ technology for dermatology applications. It represents an early-stage research program aimed at delivering biologics via a prescription topical format to treat skin conditions, potentially including acne or other inflammatory dermatoses, though specific indications remain preclinical.[5][6][9]

Beyond the preview

Go deeper on BPX-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPX-02.

Explore the full profile